welcome to cyprotex

News

September 1, 2010 - Cyprotex provides free online access to Cloe® Knowledge

Cyprotex PLC (“Cyprotex” or “the Company”)

Cyprotex Announces Free Access to Physicochemical, ADME, and Pharmacokinetic Data of Marketed Drugs Through Its Visualisation Tool, Cloe® Knowledge

Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company, today announces that it is making available to researchers free online access to Cyprotex’s database of the ADME and pharmacokinetic properties of marketed drugs via its online Cloe® Knowledge data visualisation and interpretation tool.

Free access is available via Cyprotex’s Cloe® Gateway online portal: www.cloegateway.com.

Cloe® Knowledge categorises marketed drugs according to the 2009 WHO ATC/DDD drug index, allowing the database to be searchable by therapeutic area. Cloe® Knowledge’s compound property visualisation tools allow relationships between different ADME and phys-chem properties to be viewed on either 2D or 3D scatter plots.

Commenting on the announcement, Dr Anthony D Baxter, Cyprotex's Chief Executive Officer, said:

“Cyprotex believes in sharing its knowledge with the scientific community. Our Cloe® Knowledge database of marketed drugs has been compiled and continuously updated based on extensive literature values and data generated in our own laboratories. Although some of the data are already available in the public domain, often they have not been conveniently compiled, and certainly not accessible through a powerful visualisation and interpretation tool such as the one Cloe® Knowledge provides. We believe that free access to these data via Cloe® Knowledge will help advance drug discovery, especially within the resource-constrained academic community.”

Enquiries:

Cyprotex PLC
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
Tel: +44 (0) 1625 505 100
ir@cyprotex.com
www.cyprotex.com

Singer Capital Markets Limited (broker to Cyprotex)
Tel: +44 (0) 203 205 7500
Shaun Dobson
shaun.dobson@singercm.com
Claes Spang
claes.spang@singercm.com
www.singercm.com

Financial Dynamics
Ben Brewerton
Ben Atwell
Mo Noonan
Tel: +44 (0) 20 7831 3113
cyprotex@fd.com
www.fd.com


 

view all the latest news +
2011 archive +
2010 archive +
2009 archive +
2008 archive +
2007 archive +
2006 archive +
2005 archive +
2004 archive +
2003 archive +
2002 archive +
contact

Contact us for more information on Cyprotex Discovery, including our extensive range of ADMET/PK services
and pricing.

contact
careerscontactlegalprivacy
This website was last updated
on 3rd February 2012
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.